Use this URL to cite or link to this record in EThOS: https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.780047
Title: NanoBRET to probe ligand-receptor and receptor-receptor interactions in living cells
Author: Carvalheira Alcobia, Diana
ISNI:       0000 0004 7965 7370
Awarding Body: University of Nottingham
Current Institution: University of Nottingham
Date of Award: 2019
Availability of Full Text:
Access from EThOS:
Full text unavailable from EThOS. Restricted access.
Access from Institution:
Abstract:
Increasing evidence has revealed the role of G protein-coupled receptors (GPCRs) in the regulation of signalling responses via complex cross-talk mechanisms with the receptor tyrosine kinase (RTK) family of transmembrane receptors. Vascular endothelial growth factor-a (VEGFa) mediates cancer angiogenesis via binding to its cognate VEGF receptor 2 (VEGFR2). The two class A GPCRs, adenosine A2A receptors and β2-adrenoceptors, have also been intimately involved in cancer angiogenesis, and their activation can contribute to cancer progression and invasion. However, the molecular mechanisms involved in the cross-talk between these receptor families are not well understood. Using a NanoLuc-based bioluminescence resonance energy transfer (NanoBRET) methodology, we reveal a novel mechanism in which VEGFR2 can associate with either of these Gs-coupled GPCRs to form oligomeric complexes in living cells. We also demonstrated that VEGF-stimulated VEGFR2 can induce a switch from a transient to a more stable interaction between β2AR and the adaptor protein β-arrestin-2, which may have an impact in endosomal signalling. The pharmacological inhibition of β2-adrenoceptor (β2AR) signalling, using selective β2AR antagonists (or β-blockers), represents a potential therapeutic approach for the treatment of triple-negative breast cancer variant, which has limited treatment options. This study demonstrated the novel application of NanoBRET technology to probe specific β-blocker-β2-adrenoceptor engagement in a pre-clinical in vivo model of triple-negative breast cancer. This novel methodology will allow a strong correlation between drug-target engagement and mediated physiological response.
Supervisor: Not available Sponsor: Not available
Qualification Name: Thesis (Ph.D.) Qualification Level: Doctoral
EThOS ID: uk.bl.ethos.780047  DOI: Not available
Keywords: QP Physiology
Share: